176 related articles for article (PubMed ID: 11571727)
1. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy.
Cantuaria G; Fagotti A; Ferrandina G; Magalhaes A; Nadji M; Angioli R; Penalver M; Mancuso S; Scambia G
Cancer; 2001 Sep; 92(5):1144-50. PubMed ID: 11571727
[TBL] [Abstract][Full Text] [Related]
2. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary.
Cantuaria G; Magalhaes A; Penalver M; Angioli R; Braunschweiger P; Gomez-Marin O; Kanhoush R; Gomez-Fernandez C; Nadji M
Gynecol Oncol; 2000 Oct; 79(1):33-7. PubMed ID: 11006027
[TBL] [Abstract][Full Text] [Related]
3. Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction.
Semaan A; Munkarah AR; Arabi H; Bandyopadhyay S; Seward S; Kumar S; Qazi A; Hussein Y; Morris RT; Ali-Fehmi R
Gynecol Oncol; 2011 Apr; 121(1):181-6. PubMed ID: 21167567
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
Petrillo M; Zannoni GF; Tortorella L; Pedone Anchora L; Salutari V; Ercoli A; Margariti PA; Scambia G; Fagotti A
Am J Obstet Gynecol; 2014 Dec; 211(6):632.e1-8. PubMed ID: 24954656
[TBL] [Abstract][Full Text] [Related]
5. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary.
Kurokawa T; Yoshida Y; Kawahara K; Tsuchida T; Okazawa H; Fujibayashi Y; Yonekura Y; Kotsuji F
Int J Cancer; 2004 May; 109(6):926-32. PubMed ID: 15027127
[TBL] [Abstract][Full Text] [Related]
6. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy.
Nakayama K; Kanzaki A; Terada K; Mutoh M; Ogawa K; Sugiyama T; Takenoshita S; Itoh K; Yaegashi N; Miyazaki K; Neamati N; Takebayashi Y
Clin Cancer Res; 2004 Apr; 10(8):2804-11. PubMed ID: 15102688
[TBL] [Abstract][Full Text] [Related]
8. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.
Izquierdo MA; van der Zee AG; Vermorken JB; van der Valk P; Beliën JA; Giaccone G; Scheffer GL; Flens MJ; Pinedo HM; Kenemans P
J Natl Cancer Inst; 1995 Aug; 87(16):1230-7. PubMed ID: 7563169
[TBL] [Abstract][Full Text] [Related]
10. Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study.
Davidson B; Gotlieb WH; Ben-Baruch G; Kopolovic J; Goldberg I; Nesland JM; Berner A; Bjåmer A; Bryne M
Gynecol Oncol; 2000 Apr; 77(1):35-43. PubMed ID: 10739688
[TBL] [Abstract][Full Text] [Related]
11. Expression of glucose transporter-1 in cervical cancer and its precursors.
Mendez LE; Manci N; Cantuaria G; Gomez-Marin O; Penalver M; Braunschweiger P; Nadji M
Gynecol Oncol; 2002 Aug; 86(2):138-43. PubMed ID: 12144819
[TBL] [Abstract][Full Text] [Related]
12. [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors].
Cai Y; Shao SL; Wang QH; Yan LJ; Wang XY; Wang LX
Ai Zheng; 2007 Nov; 26(11):1188-93. PubMed ID: 17991316
[TBL] [Abstract][Full Text] [Related]
13. Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma.
Srivatsa PJ; Cliby WA; Keeney GL; Dodson MK; Suman VJ; Roche PC; Podratz KC
Gynecol Oncol; 1996 Mar; 60(3):363-72. PubMed ID: 8774640
[TBL] [Abstract][Full Text] [Related]
14. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
[TBL] [Abstract][Full Text] [Related]
15. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
17. GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer.
Rudlowski C; Moser M; Becker AJ; Rath W; Buttner R; Schroder W; Schurmann A
Oncology; 2004; 66(5):404-10. PubMed ID: 15331928
[TBL] [Abstract][Full Text] [Related]
18. Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions.
Davidson B; Berner A; Trope' CG; Wang TL; Shih IM
Hum Pathol; 2007 Jul; 38(7):1030-1036. PubMed ID: 17391728
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside transporters are widely expressed in ovarian carcinoma effusions.
Bock AJ; Dong HP; Tropé CG; Staff AC; Risberg B; Davidson B
Cancer Chemother Pharmacol; 2012 Feb; 69(2):467-75. PubMed ID: 21822668
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
